Biocon Limited’s long-standing partner in Malaysia, Duopharma Biotech Berhad, has secured multiple insulin supply contracts from Malaysia’s Ministry of Health worth more than MYR 225 million, strengthening access to essential diabetes treatments in the country. The contracts cover human insulin, insulin glargine and insulin aspart, and will be supplied through Biocon’s Malaysian subsidiary, Biocon Sdn. Bhd., for distribution across the public healthcare system.
The development comes at a time when Malaysia continues to face a substantial diabetes burden, with the partnership playing a key role in ensuring a steady and affordable insulin supply. Biocon said the latest awards reinforce its commitment to diabetes care in Malaysia and highlight the importance of local manufacturing in improving medicine security. The company added that its Johor facility remains central to its insulin operations and broader global supply network.
Shreehas Tambe, CEO & Managing Director, Biocon Limited, said: “Malaysia has been central to Biocon’s insulin journey for over a decade, anchored by our integrated insulin manufacturing facility in the country- the largest in Asia. Our Johor operations enable us to deliver insulin at scale, expanding patient access in Malaysia and around the world. This reinforces our strategy to address growing healthcare needs while advancing our mission of making life-changing medicines affordable and accessible to patients everywhere.”
Joe Sian, Site Head, Biocon Sdn. Bhd., said: “Biocon’s partnership with Duopharma Biotech has helped expand access to insulin therapies for patients in Malaysia. With an estimated 4.75 million people living with diabetes in the country, ensuring an affordable insulin supply is essential. This collaboration enables us to support patients across our full portfolio of insulin products.”
Encik Wan Amir-Jeffery Wan Abdul Majid, GCEO, Duopharma Biotech Berhad, said: “Duopharma Biotech is delighted and honoured to mark a decade in supporting the healthcare ecosystem together with our long-standing partner- Biocon, alongside welcoming new contracts to supply insulin products to Malaysian patients. It is more critical than ever to have robust domestic pharmaceutical manufacturing capacity to safeguard patient access to essential medicines, strengthening national medicine security and achieving healthcare self-reliance for the country.”
The contracts underline the continuing importance of Biocon-Duopharma collaboration in supporting Malaysia’s public healthcare needs while expanding access to life-saving diabetes medicines at scale.
